pp-240 Injection
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: IgA Nephropathy (IgAN), Anti-PLA2R MPGN, FSGS, Minimal Change Disease, Lupus Nephritis / Clinical stage: Phase 3 / Modality: Biologic - fusion protein (BAFF/APRIL antagonist) / Mechanism & Target: Dual BAFF/APRIL inhibition for B-cell modulation / Route & form: SC once weekly / Differentiation: First-in-class B-cell modulator in IgAN; home-administered
Manufacturer #39443
| Clinical-stage biopharmaceutical company focused on autoimmune kidney diseases. Develops dual-targeting biologics inhibiting key mediators of IgA nephropathy and lupus nephritis. Lead Phase 3 program holds FDA Breakthrough Therapy designation. |
None